Segment Reporting (Details) - Schedule of Segment Profitability That Are Most Relied Upon By the Codm Are Gross Revenues and Net Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Dominari Financial [Member]
Segment Reporting Information [Line Items]
Revenue	$ 2,039
General and administrative	15,750	157
Research and development
Loss from operations	(13,711)	(157)
Other (expenses) income
Other income
Interest income	229
Gain on marketable securities
Unrealized loss on note receivable
Change in fair value of investments
Total other (expenses) income	229
Net loss	(13,482)	(157)
Legacy AIkido Pharma [Member]
Segment Reporting Information [Line Items]
Revenue
General and administrative	8,088	11,526
Research and development	(3)	2,663
Loss from operations	(8,085)	(14,189)
Other (expenses) income
Other income	36	64
Interest income	487	687
Gain on marketable securities	630	(5,952)
Unrealized loss on note receivable	(3,248)
Change in fair value of investments	780	(2,560)
Total other (expenses) income	(1,315)	(7,761)
Net loss	(9,400)	(21,950)
Consolidated [Member]
Segment Reporting Information [Line Items]
Revenue	2,039
General and administrative	23,839	11,683
Research and development	(3)	2,663
Loss from operations	(21,797)	(14,346)
Other (expenses) income
Other income	36	64
Interest income	716	687
Gain on marketable securities	630	(5,952)
Unrealized loss on note receivable	(3,248)
Change in fair value of investments	780	(2,560)
Total other (expenses) income	(1,086)	(7,761)
Net loss	$ (22,882)	$ (22,107)